Related Experiment Video
Updated: Dec 10, 2025
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.9K
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Radu O Minea1, Tuan Cao Duc2, Stephen D Swenson1
1Department of Neurological Surgery, Keck School of Medicine (KSOM), University of Southern California (USC), Los Angeles, California (CA), United States of America.
Plos One
|September 4, 2020
Summary
A new drug, NEO212, shows promise in treating glioblastoma by enhancing tumor cell uptake and DNA alkylation, offering improved radiosensitization independent of MGMT status.
Area of Science:
- Oncology
- Neuro-oncology
- Cancer Therapeutics
Background:
- Glioblastoma (GB) prognosis remains poor, with current standard-of-care temozolomide (TMZ) and radiation offering limited survival benefits.
- TMZ's efficacy is hindered by O6-methylguanine DNA methyltransferase (MGMT) repair and limited radiosensitization at physiologic concentrations.
- Non-O6-methylguanine lesions, though numerous, are not effectively exploited by TMZ for radiosensitization due to repair mechanisms.
Purpose of the Study:
- To develop and evaluate NEO212, a novel TMZ derivative, as a potential glioblastoma therapeutic agent.
- To assess NEO212's efficacy in overcoming TMZ resistance and enhancing radiosensitization.
- To investigate NEO212's pharmacokinetic profile, including blood-brain barrier penetration and tumor accumulation.
Main Methods:
- NEO212 was synthesized by coupling temozolomide (TMZ) with perillyl alcohol.
- Gas chromatography/mass spectrometry and high-performance liquid chromatography were used for analysis.
- In vitro studies utilized glioblastoma cell lines (including TMZ-resistant variants), and in vivo studies employed mouse models.
Main Results:
- NEO212 demonstrated greater tumor cell uptake and enhanced blood-brain barrier penetration compared to TMZ.
- NEO212 exhibited superior cytotoxic and radiosensitizing activities at physiologic concentrations in vitro.
- NEO212's radiosensitizing effect is attributed to enhanced DNA alkylation, effectively exploiting N-methylpurine lesions independently of MGMT status.
Conclusions:
- NEO212 represents a promising alternative to TMZ for glioblastoma treatment, offering improved efficacy and radiosensitization.
- The drug's effectiveness is independent of MGMT expression, addressing a key limitation of current TMZ therapy.
- NEO212 warrants further investigation as a superior radiosensitizer for newly diagnosed glioblastoma patients.
